Spots Global Cancer Trial Database for Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma
Official Title: Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma
Study ID: NCT05187884
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the feasibility and tolerability of neo-adjuvant/adjuvant Darovasertib on uveal melanoma patients. Who is it for? Patients may be eligible to join this study with high-risk uveal melanoma and planned to undergo enucleation Study details: Eligible patients will undergo up to 4 weeks of treatment with Darovasertib (300mg, twice a day as a starting dose) and once determiend safe then up to 6 months after fulfilling inclusion/exclusion criteria and consent. Select patients will undergo adjuvant treatment for 6 months based on their initial response. It is hoped that this research will provide insight into the safety and tolerability of Darovasertib. Furthermore, it aims to document the pharmacodynamic and pharmacokinectic effects of Darovasertib on uveal melanoma patients.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia
Alfred Hospital, Melbourne, Victoria, Australia
Contact Details
Name: Anthony Joshua, FRACP, MBBS, PhD
Affiliation: St Vincent's Hospital, Sydney
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
